Conmed (CNMD) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
CONMED (CNMD) PT Raised to $158 at Needham & Company
October 28, 2021 6:22 AM EDTNeedham & Company analyst Mike Matson raised the price target on CONMED (NASDAQ: CNMD) to $158.00 (from $150.00) while maintaining a Buy rating.
The analyst commented, "CNMD's 3Q21 revenue missed and EPS beat consensus. Management guided to the low-end of its prior revenue guidance range and... More
